CLDN4 and breast carcinoma: Using Claudin-4 as a target for fluorescent molecules, c-CPE bound to NP (c-CPE NP) can be further localized and administered intraperitoneally (IP) in breast cancer cells to significantly lessen systemic toxicity than with the same dose administered intravenously.